Statins as Adjunctive, Host-Directed Therapy for TB


10/01/2017 - 09/30/2020


Petros Karakousis, MD

The goal of this study is to investigate the potential utility of pravastatin as an adjunctive, host-directed therapy for drug-susceptible pulmonary TB in a two-stage randomized control trial. The primary outcomes of the Stage 1 study are safety and toxicity, and will allow the selection of pravastatin dose for the Stage 2 efficacy study. In the latter, the primary outcomes will include median time to sputum culture conversion and the serial assessment of various subjective and objective measures of lung function. We are also investigating the anti-TB mechanism of action of statins using a variety of high-throughput and targeted molecular approaches.


Modeling the impact of novel TB drug regimens...

We are constructing mathematical models of TB epidemics in Southeast Asia, India, and Vietnam to explore the potential...

Read More

TBM-KIDS (India)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

Evaluation of a novel serum biosignature for...

This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites...

Read More

APT: Assessing PA-824 for Tuberculosis

A Phase 2 clinical trial of PA-824, an investigational nitroimidazole, as part of multidrug therapy for pulmonary TB; in...

Read More